 Shares of Arbutus Biopharma NASDAQ:ABUS fell 1 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 45.65 over the past year to 0.25, which missed the estimate of 0.24.Revenue of 1,514,000 up by 116.29 from the same period last year, which missed the estimate of 1,740,000.Looking Ahead Arbutus Biopharma hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Details Of The Call Date: Aug 07, 2020View more earnings on ABUSTime: 07:30 AMET Webcast URL: Action 52-week high: 9.0252-week low: 0.82Price action over last quarter: Up 184.85Company Description Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.See more from Benzinga Earnings Scheduled For August 7, 2020 Stocks That Hit 52-Week Highs On Friday 17 Healthcare Stocks Moving In Mondays Pre-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 